We hold the whole span: discovery through approval and launch, with the same team accountable at every stage gate.
PIER 01
Discovery & design
Discovery and lead-optimization support with phase-appropriate formulation design. Programs set up to succeed from the first batch.
PIER 02
Engineer the span
Scale-up, tech-transfer, validation and clinical bioequivalence. The load-bearing work that makes a formulation manufacturable and approvable.
PIER 03
File & launch
eCTD filings for the US and EU, approval support and launch. Bench to commercial, one continuous crossing.
Why partner with Credence
One team, accountable for the whole crossing.
01
Holistic, integrated development
One accountable team from discovery through approval. No handoffs between vendors, no gaps where a program stalls, no finger-pointing when a timeline slips.
02
Science and commercial success, together
Development decisions made with the P&L in view. We have carried products to market and sat on the commercial side of the table, so formulation, CDMO contract and launch economics get weighed together.
03
Genuinely unbiased
No manufacturing stake, no CDMO referral fees, no commercial agenda.
04
An extended R&D team, on your terms
Consulting built as an extension of your own R&D group, with advisory matched to where the program actually stands, phase by phase and stage by stage. Engage us on a fee-for-service basis or as dedicated FTEs, scoped to suit the project and the way your team works.
Want to know how we would approach your program? Tell us where it stands.
Credible partners for pharmaceutical & life-sciences clients. Evidence-led advisory in CMC, regulatory, quality and strategy for NCEs, generics and branded-generics.